CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03759288
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-24T00:04:43.106334+00:00
Published At: 2026-06-23T00:00:00+00:00
Record Updated At: 2026-06-23
Results Posted At: 2026-06-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Crohn\u0027s Disease", "IBD"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-23"
protocolSection.identificationModule.nctId: "NCT03759288"
protocolSection.identificationModule.officialTitle: "A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn\u0027s Disease (INTREPID Lead-In)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-06-23"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.